EP1423122A4 - Zusammensetzungen und verfahren in verbindung mit neuen benzodiazepin-verbindungen und ihre ziele - Google Patents

Zusammensetzungen und verfahren in verbindung mit neuen benzodiazepin-verbindungen und ihre ziele

Info

Publication number
EP1423122A4
EP1423122A4 EP02794914A EP02794914A EP1423122A4 EP 1423122 A4 EP1423122 A4 EP 1423122A4 EP 02794914 A EP02794914 A EP 02794914A EP 02794914 A EP02794914 A EP 02794914A EP 1423122 A4 EP1423122 A4 EP 1423122A4
Authority
EP
European Patent Office
Prior art keywords
targets
compositions
methods relating
benzodiazepine compounds
novel benzodiazepine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02794914A
Other languages
English (en)
French (fr)
Other versions
EP1423122A2 (de
Inventor
Gary D Glick
Anthony W Opipari
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan
Original Assignee
University of Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/217,878 external-priority patent/US20030119029A1/en
Application filed by University of Michigan filed Critical University of Michigan
Publication of EP1423122A2 publication Critical patent/EP1423122A2/de
Publication of EP1423122A4 publication Critical patent/EP1423122A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
EP02794914A 2001-08-15 2002-08-15 Zusammensetzungen und verfahren in verbindung mit neuen benzodiazepin-verbindungen und ihre ziele Withdrawn EP1423122A4 (de)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US217878 1998-12-21
US31256001P 2001-08-15 2001-08-15
US312560P 2001-08-15
US31368901P 2001-08-20 2001-08-20
US313689P 2001-08-20
US39667002P 2002-07-18 2002-07-18
US396670P 2002-07-18
US10/217,878 US20030119029A1 (en) 1999-04-30 2002-08-13 Compositions and methods relating to novel benzodiazepine compounds and targets thereof
PCT/US2002/026171 WO2003015703A2 (en) 2001-08-15 2002-08-15 Compositions and methods relating to novel benzodiazepine compounds and targets thereof

Publications (2)

Publication Number Publication Date
EP1423122A2 EP1423122A2 (de) 2004-06-02
EP1423122A4 true EP1423122A4 (de) 2008-12-10

Family

ID=27499087

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02794914A Withdrawn EP1423122A4 (de) 2001-08-15 2002-08-15 Zusammensetzungen und verfahren in verbindung mit neuen benzodiazepin-verbindungen und ihre ziele

Country Status (8)

Country Link
EP (1) EP1423122A4 (de)
JP (1) JP2005502652A (de)
AU (1) AU2002332560B2 (de)
CA (1) CA2457405A1 (de)
MX (1) MXPA04001421A (de)
NO (1) NO20041058L (de)
NZ (1) NZ531117A (de)
WO (1) WO2003015703A2 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060025388A1 (en) * 1999-04-30 2006-02-02 Glick Gary D Compositions and methods relating to novel compounds and targets thereof
ES2214273T3 (es) 1999-04-30 2004-09-16 The Regents Of The University Of Michigan Utilizacion de benzodiazepinas para el tratamiento de enfermedades autoinmunes inducidas por apoptosis.
US20050113460A1 (en) * 1999-04-30 2005-05-26 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
US7572788B2 (en) 1999-04-30 2009-08-11 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
US7276348B2 (en) 1999-04-30 2007-10-02 Regents Of The University Of Michigan Compositions and methods relating to F1F0-ATPase inhibitors and targets thereof
WO2005004988A2 (en) * 2003-05-01 2005-01-20 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
US20050272723A1 (en) * 2004-04-27 2005-12-08 The Regents Of The University Of Michigan Methods and compositions for treating diseases and conditions associated with mitochondrial function
JP2008528448A (ja) 2005-01-03 2008-07-31 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 新規化合物に関連する組成物および方法、ならびにその標的
JP2008545757A (ja) * 2005-06-01 2008-12-18 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 溶媒和されていないベンゾジアゼピン組成物および方法
MX2008003369A (es) * 2005-09-19 2008-03-27 Arrow Therapeutics Ltd Derivados de benzodiazepina para tratar infeccion de hepatitis c.
JP5241501B2 (ja) 2005-11-01 2013-07-17 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 治療特性を有する新規の１，４−ベンゾジアゼピン−２，５−ジオン
US7759338B2 (en) 2006-04-27 2010-07-20 The Regents Of The University Of Michigan Soluble 1,4 benzodiazepine compounds and stable salts thereof
EP2037741B1 (de) 2006-06-09 2013-11-27 The Regents Of The University Of Michigan Benzodiazepin-derivate zur behandlung von krankheiten auf immun-, inflammatorischer oder proliferativer basis
EP2139331B1 (de) 2007-03-09 2013-02-20 The Regents of the University of Michigan Zusammensetzungen und verfahren für neue verbindungen und ihre targets
CN101855203B (zh) 2007-09-14 2014-03-19 密执安州立大学董事会 F1f0-atp合成酶抑制剂以及相关的方法
CA2703005A1 (en) 2007-11-06 2009-05-14 The Regents Of The University Of Michigan Benzodiazepinone compounds useful in the treatment of skin conditions
WO2010030891A2 (en) 2008-09-11 2010-03-18 The Regents Of The University Of Michigan Aryl guanidine f1f0-atpase inhibitors and related methods
WO2010121164A2 (en) 2009-04-17 2010-10-21 The Regents Of The University Of Michigan 1,4-benzodiazepinone compounds and their use in treating cancer
US8673897B2 (en) 2009-09-18 2014-03-18 The Regents Of The University Of Michigan Benzodiazepinone compounds and methods of treatment using same
JP5856064B2 (ja) 2009-11-17 2016-02-09 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 治療特性を有する１，４−ベンゾジアゼピン−２，５−ジオンおよび関連化合物
CA2915237C (en) 2009-11-17 2017-10-10 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4898861A (en) * 1987-03-26 1990-02-06 Hoffmann-La Roche Inc. Method for inhibiting the proliferation of tumor cells
US5776946A (en) * 1995-08-28 1998-07-07 Mcgeer; Patrick L. Peripheral benzodiazepine receptor ligands as antiinflammatory agents
WO1999058117A1 (fr) * 1998-05-13 1999-11-18 Sanofi-Synthelabo Utilisation de composes reduisant l'apoptose
WO1999066958A2 (fr) * 1998-06-22 1999-12-29 Centre National De La Recherche Scientifique (Cnrs) Utilisation d'un compose possedant une affinite pour le recepteur mitochondrial des benzodiazepines en therapie du cancer
WO2000066106A2 (en) * 1999-04-30 2000-11-09 The Regents Of The University Of Michigan Use of benzodiazepines for treating autoimmune diseases induced by apoptosis
WO2001051922A2 (en) * 2000-01-14 2001-07-19 Mitokor Identification of peripheral benzodiazepine receptor binding agents

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277844B1 (en) * 1998-09-14 2001-08-21 Sydney Spector Compound for selective treatment of malignant cells by inhibiting cell cycle progression, decreasing Bcl2, and increasing apoptosis
EP1210596A2 (de) * 1999-06-22 2002-06-05 Mitokor Verfahren zur untersuchung subzellulärer zustände mit hilfe von energietransfer
US7005274B1 (en) * 1999-09-15 2006-02-28 Migenix Corp. Methods and compositions for diagnosing and treating arthritic disorders and regulating bone mass

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4898861A (en) * 1987-03-26 1990-02-06 Hoffmann-La Roche Inc. Method for inhibiting the proliferation of tumor cells
US5776946A (en) * 1995-08-28 1998-07-07 Mcgeer; Patrick L. Peripheral benzodiazepine receptor ligands as antiinflammatory agents
WO1999058117A1 (fr) * 1998-05-13 1999-11-18 Sanofi-Synthelabo Utilisation de composes reduisant l'apoptose
WO1999066958A2 (fr) * 1998-06-22 1999-12-29 Centre National De La Recherche Scientifique (Cnrs) Utilisation d'un compose possedant une affinite pour le recepteur mitochondrial des benzodiazepines en therapie du cancer
WO2000066106A2 (en) * 1999-04-30 2000-11-09 The Regents Of The University Of Michigan Use of benzodiazepines for treating autoimmune diseases induced by apoptosis
WO2001051922A2 (en) * 2000-01-14 2001-07-19 Mitokor Identification of peripheral benzodiazepine receptor binding agents

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BLUM P ET AL: "STIFF-PERSON SYNDROME: AN AUTOIMMUNE DISEASE", MOVEMENT DISORDERS, RAVEN PRESS, NEW YORK, NY, US, vol. 6, no. 1, 1 January 1991 (1991-01-01), pages 12 - 20, XP000957552, ISSN: 0885-3185 *
SCHLUMPF M ET AL: "DELAYED DEVELOPMENTAL IMMUNOTOXICITY OF PRENATAL BENZODIAZEPINES", TOXICOLOGY IN VITRO, ELSEVIER SCIENCE, GB, vol. 8, no. 5, 1 January 1994 (1994-01-01), pages 1061 - 1065, XP000957564, ISSN: 0887-2333 *
SHAWN Y. STEVENS ET AL.: "Non nucleic acis inhibitors of protein-DNA interactions identified through combinatorial chemistry", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 118, 1996, pages 10650 - 10651, XP002499663 *
TANIMOTO Y ET AL: "BENZODIAZEPINE RECEPTOR AGONISTS MODULATE THYMOCYTE APOPTOSIS THROUGH REDUCTION OF THE MITOCHONDRIAL TRANSMEMBRANE POTENTIAL", JAPANESE JOURNAL OF PHARMACOLOGY, JP, vol. 79, no. 2, 1 January 1999 (1999-01-01), pages 177 - 183, XP000957554, ISSN: 0021-5198 *

Also Published As

Publication number Publication date
MXPA04001421A (es) 2004-06-03
JP2005502652A (ja) 2005-01-27
NZ531117A (en) 2006-03-31
CA2457405A1 (en) 2003-02-27
WO2003015703A3 (en) 2003-11-13
NO20041058L (no) 2004-05-14
AU2002332560B2 (en) 2006-01-19
WO2003015703A2 (en) 2003-02-27
EP1423122A2 (de) 2004-06-02

Similar Documents

Publication Publication Date Title
EP1423122A4 (de) Zusammensetzungen und verfahren in verbindung mit neuen benzodiazepin-verbindungen und ihre ziele
EP1409619A4 (de) Verbundwerkstoffzusammensetzungen
EP1622684A4 (de) Zusammensetzungen und verfahren für neue verbindungen und ihre targets
PL367134A1 (en) Novel composition
GB0114069D0 (en) Composition
GB0112925D0 (en) Improvements in or relating to compositions
EG23126A (en) Novel fungicial compositions
GB0107651D0 (en) Composition
GB0114532D0 (en) Novel compositions
EP1364646A4 (de) Fenofibrat enthaltende zusammensetzung
GB0124728D0 (en) Improvements in or relating to compositions
GB0115679D0 (en) Composition
GB0117305D0 (en) Composition
GB0211949D0 (en) Novel compounds compositions and processes
GB0031267D0 (en) Novel compositions
GB0101480D0 (en) Improvements and or relating to organic compositions
HUP0501091A2 (en) Solid composition
GB0122906D0 (en) Compounds and compositions
GB0027444D0 (en) Novel compound compositions and processes
GB0112877D0 (en) New compositions of matter
GB0112874D0 (en) New compositions of Matter
SI1418942T1 (sl) Sestavki, ki vsebujejo poksvirus, in postopek za njihovo pripravo
GB0000916D0 (en) New compositions of matter
GB0119468D0 (en) Novel composition
GB0119470D0 (en) Novel composition

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040308

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20081106

17Q First examination report despatched

Effective date: 20090529

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20091209